Form of Amendment and Restatement of the Vaccinex, Inc. Common Stock Purchase Warrant (November 2023, as amended March 2024)
Exhibit 4.4
AMENDMENT AND RESTATEMENT
OF THE
VACCINEX, INC.
COMMON STOCK PURCHASE WARRANT
This Amendment and Restatement (this “Amendment”), dated as of [], 2024 (the “Effective Date”), is made and entered into by and between Vaccinex, Inc., a Delaware corporation (the “Company”), and [] (the “Holder”) and amends the Common Stock Purchase Warrant to purchase up to [] shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at an exercise price of $[] per share, originally issued by the Company to the Holder on [], 202[3][4] (such number and price, as adjusted to reflect the Company’s February 19, 2024 reverse stock split (the “Reverse Stock Split”)) (the “Warrant”).
WHEREAS, the Holder is the holder of the Warrant; and
WHEREAS, the Holder and the Company have agreed to amend and restate the Warrant pursuant to the provisions of Section 5(l) of the Warrant.
NOW, THEREFORE, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
c. Continuation of the Warrant. Except as expressly modified by this Amendment, the Warrant shall continue to be and remain in full force and effect in accordance with its terms. Any future reference to the Warrant shall be deemed to be a reference to the Warrant as modified by this Amendment.
(signature pages follow)
- 2 -
IN WITNESS WHEREOF, the undersigned has executed this Amendment as of the date first written above.
VACCINEX, INC.
By:________________________________ Name: Maurice Zauderer
Title: President and Chief Executive Officer
IN WITNESS WHEREOF, the undersigned has executed this Amendment as of the date first written above.
HOLDER NAME
By:________________________________ Name:
Title:
Exhibit A
Amendment and Restatement
(See attached)